UNSPSC 51261502: Cetamolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z0VD1633O8 chemically known as acetamide, 2-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenoxy)-n-methyl-, (+/-)- but generally known as cetamolol, which bears US NIH Compound Identifier 53698. European Medicines Agency schedules Cetamolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07446MIG.

UNSPSC 51261502 Cetamolol is a Commodity code that encompasses pharmaceutical products, though recent state and local solicitations show minimal direct activity under this specific code. The Commodity sits within a broader pharmaceutical and medical-supply procurement landscape where state and local health agencies and county health departments procure medications and drug-management systems to support community health initiatives and pharmacy benefit programs. When activity does occur under related pharmaceutical codes, issuing bodies include county health departments, state health and human services commissions, and special-purpose health authorities managing public health operations and employee benefit programs.

Recent opportunities show sparse direct alignment with the cetamolol code itself. Seminole County, Florida posted an IFB (No. IFB60459723LAS) on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a due date of July 26, 2023—procured for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs to support state pharmacy benefit operations. Neither solicitation directly targets cetamolol; the Seminole County opportunity focuses on opioid-reversal and drug-deactivation systems, while the Texas RFI addresses pharmacy contracting mechanisms and cost management. Geographic activity is concentrated in Florida and Texas based on recent posts, though the code shows limited recent state and local contract activity overall. State and local buyers pursuing pharmaceutical procurement should monitor this code for health department and HHS commission solicitations, but current market signals suggest relatively low purchasing velocity under the cetamolol designation specifically.